{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:01:59Z","timestamp":1784523719431,"version":"3.55.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To determine the safety and tolerance of an allogeneic, pooled freeze-dried platelet-rich plasma (PRP; VetStem PrecisePRP\u2122 Canine) product administered via subconjunctival injection two weeks apart in clinically normal canine eyes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Allogeneic PRP was reconstituted with sterile water. With topical anesthesia and gentle manual restraint of each dog, 0.2\u202fmL (500 \u00d7 10\n                      <jats:sup>6<\/jats:sup>\n                      platelets\/mL) of the reconstituted preparation was injected under the dorsal bulbar conjunctiva of the right eye. The procedure was repeated with 0.2\u202fmL of sterile saline (control) under the dorsal bulbar conjunctiva of the left eye. A complete blood count, chemistry profile, and comprehensive physical and ophthalmic examinations were conducted on all dogs at multiple time points to monitor for potential adverse reactions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No significant adverse effects associated with physical examination, hematologic or ocular parameters were noted at any time point during the study. All allogeneic PRP treated eyes developed a mild to moderate conjunctival hyperemia and chemosis that self-resolved within 48\u201372\u202fh. Additionally, one eye developed a mild periocular hyperemia that self-resolved within 72\u202fh. No adverse reaction was noted in any saline treated eye.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Allogeneic PRP administered via subconjunctival injection in normal canine eyes appears to be safe and well-tolerated with only transient conjunctival hyperemia and chemosis noted. This study allows for further investigation into the clinical efficacy of subconjunctival allogeneic PRP for canine ocular surface inflammatory disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fvets.2026.1870669","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T04:20:24Z","timestamp":1784521224000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety of subconjunctival allogeneic platelet-rich plasma on normal canine eyes"],"prefix":"10.3389","volume":"13","author":[{"given":"Amanda B.","family":"Davis","sequence":"first","affiliation":[{"name":"Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia L.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby A.","family":"Hickox","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"240","DOI":"10.12968\/coan.2019.24.5.240","article-title":"Ocular surface disease in dogs part 1: aetiopathogenesis and clinical signs","volume":"24","author":"Maggio","year":"2021","journal-title":"Companion Anim"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1067942","DOI":"10.3389\/ftox.2023.1067942","article-title":"Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy","volume":"5","author":"Ruiz-Lozano","year":"2023","journal-title":"Front Toxicol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/00008505-200110000-00002","article-title":"Platelet-rich plasma (PRP): what is PRP and what is not PRP?","volume":"10","author":"Marx","year":"2001","journal-title":"Implant Dent"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s11259-022-10064-z","article-title":"Advances and prospects of platelet-rich plasma therapy in veterinary ophthalmology","volume":"47","author":"Sharun","year":"2023","journal-title":"Vet Res Commun"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.22092\/ari.2021.355953.1749","article-title":"Therapeutic potential of platelet-rich plasma in canine medicine","volume":"76","author":"Sharun","year":"2021","journal-title":"Arch Razi Inst"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1177\/154405910508400507","article-title":"Platelet-rich plasmas: growth factor content and roles in wound healing","volume":"84","author":"Frechette","year":"2006","journal-title":"J Dent Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.14202\/vetworld.2025.1262-1273","article-title":"Injectable homologous platelet-rich plasma, alone or in combination with oral omega-3 supplementation, for treating keratoconjunctivitis sicca in dogs","volume":"18","author":"Villa","year":"2025","journal-title":"Vet World"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.17582\/journal.jahp\/2020\/8.1.1.7","article-title":"Effect of autologous plasma treatment on the cornea regeneration with keratoconjunctivitis sicca in dogs","volume":"8","author":"Vatnikov","year":"2020","journal-title":"J Animal Health Product"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.2147\/OPTH.S265701","article-title":"Human platelets and derived products in treating ocular surface diseases \u2013 a systematic review","volume":"14","author":"You","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"9921619","DOI":"10.1155\/vmi\/9921619","article-title":"Platelet-rich plasma for the treatment of ocular surface disease in animals: a systematic review","volume":"2025","author":"Uribe","year":"2025","journal-title":"Vet Med Int"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.14202\/vetworld.2023.134-143","article-title":"Comparison of topical 0.03% tacrolimus and homologous injectable platelet-rich plasma in the treatment of keratoconjunctivitis sicca in dogs","volume":"16","author":"Estanho","year":"2023","journal-title":"Vet World"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.2174\/138920112800624355","article-title":"The role of \u201ceye platelet rich plasma\u201d (E-PRP) for wound healing in ophthalmology","volume":"13","author":"Alio","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.3390\/ijms21207794","article-title":"Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020","volume":"21","author":"Everts","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13028-016-0226-3","article-title":"The influence of environmental variables on platelet concentration in horse platelet-rich plasma","volume":"58","author":"Rinnovati","year":"2016","journal-title":"Acta Vet Scand"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000514223","article-title":"Allogeneic platelet-rich plasma: is it safe and effective for wound repair?","volume":"62","author":"Akbarzadeh","year":"2021","journal-title":"Eur Surg Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3727\/096368912X653183","article-title":"The potential use of allogeneic platelet-rich plasma for large bone defect treatment: immunogenicity and defect healing efficacy","volume":"22","author":"Zhang","year":"2013","journal-title":"Cell Transplant"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1111\/trf.15535","article-title":"Allogeneic platelet-rich plasma (PRP) is superior to platelets or plasma alone in stimulating fibroblast proliferation and migration, angiogenesis, and chemotaxis as relevant processes for wound healing","volume":"59","author":"van der Bijl","year":"2019","journal-title":"Transfusion"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12917-022-03225-4","article-title":"A safety evaluation of allogeneic freeze-dried platelet-rich plasma or conditioned serum compared to autologous frozen products equivalents in equine healthy joints","volume":"18","author":"Garbin","year":"2022","journal-title":"BMC Vet Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1216190","DOI":"10.3389\/fpain.2023.1216190","article-title":"Allogenic platelet-rich plasma for treatment of knee and hip osteoarthritis","volume":"4","author":"Gupta","year":"2023","journal-title":"Front Pain Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.transci.2014.12.027","article-title":"Platelet-rich plasma as treatment for persistent ocular epithelial defects","volume":"52","author":"Ronci","year":"2015","journal-title":"Transfus Apher Sci"},{"key":"ref21","first-page":"1","volume-title":"Veterinary Allogeneic Platelet-Rich Plasma Safety Overview. VetStem Incorporated Statement","author":"Harman","year":"2023"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1007\/s40123-025-01211-1","article-title":"Real-world outcomes of allogeneic immunosafe plasma rich in growth factors eye drops for refractory ocular surface diseases: a prospective observational study","volume":"14","author":"Alvarado-Villacorta","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1590\/1678-4162-12214","article-title":"Allogenic platelet-rich plasma in induced ulcers in rat\u2019s cornea","volume":"73","author":"Gandolfi","year":"2021","journal-title":"Arq Bras Med Vet Zootec"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3109\/02713683.2014.978478","article-title":"Platelet-rich plasma prolongs myofibroblast accumulation in corneal stroma with incisional wound","volume":"40","author":"Koulikovska","year":"2015","journal-title":"Curr Eye Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1215848","DOI":"10.3389\/fopht.2023.1215848","article-title":"Use of allogeneic platelet-rich plasma for the treatment of autoimmune ocular surface disorders: case series","volume":"3","author":"Mancini","year":"2023","journal-title":"Front Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/ICO.0b013e3180645cd7","article-title":"Allogeneic serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease","volume":"26","author":"Chiang","year":"2007","journal-title":"Cornea"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/sj.eye.6703079","article-title":"Allogeneic serum eye drops for the treatment of persistent corneal epithelial defect","volume":"23","author":"Chiang","year":"2009","journal-title":"Eye"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1089\/jop.2012.0002","article-title":"Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease","volume":"28","author":"Na","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40123-017-0100-z","article-title":"Treatment of dry eye disease with autologous platelet-rich plasma: a prospective, interventional, non-randomized study","volume":"6","author":"Alio","year":"2017","journal-title":"Ophthalmol Ther"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3341\/kjo.2016.30.2.101","article-title":"Autologous platelet-rich plasma eye drops in the treatment of recurrent corneal erosions","volume":"30","author":"Lee","year":"2016","journal-title":"Korean J Ophthalmol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4103\/JNMO.JNMO_64_25","article-title":"Subconjunctival versus topical platelet-rich plasma for dry eye: retrospective study","volume":"20","author":"Agarwal","year":"2026","journal-title":"NMO Journal"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/17460751.2025.2544486","article-title":"Sustained long-term benefits of autologous subconjunctival platelet-rich plasma injections for severe dry eye disease","volume":"20","author":"Mora","year":"2025","journal-title":"Regen Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"641265","DOI":"10.3389\/fvets.2021.641265","article-title":"Corneal ulcer in dogs and cats: novel clinical application of regenerative therapy using subconjunctival injection of autologous platelet-rich plasma","volume":"8","author":"Farghali","year":"2021","journal-title":"Front Vet Sci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1142\/s1682648518720034","article-title":"Case report: subconjunctival injection with autologous platelet-rich plasma for refractory corneal ulcers in a dog","volume":"44","author":"Yang","year":"2018","journal-title":"Taiwan Vet J"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-3-319-78364-2_5","volume-title":"Standards for Ocular Toxicology and Inflammation","author":"Eaton","year":"2018"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/term.2361","article-title":"Allogeneic platelet-rich plasma affects monocyte differentiation to dendritic cells causing an anti-inflammatory microenvironment, putatively fostering wound healing","volume":"12","author":"Papait","year":"2018","journal-title":"J Tissue Eng Regen Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"096368972093142","DOI":"10.1177\/0963689720931428","article-title":"Comparison of allogeneic platelet-rich plasma with autologous platelet-rich plasma for the treatment of diabetic lower extremity ulcers","volume":"29","author":"He","year":"2020","journal-title":"Cell Transplant"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jss.2019.09.019","article-title":"Allogeneic platelet-rich plasma therapy as an effective and safe adjuvant method for chronic wounds","volume":"246","author":"Liao","year":"2020","journal-title":"J Surg Res"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1694691","DOI":"10.3389\/fendo.2025.1694691","article-title":"Progress in the clinical application of allogeneic platelet-rich plasma for diabetic foot treatment","volume":"16","author":"Qin","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1186\/s12891-022-06073-3","article-title":"Efficacy of intra-articular injection of allogeneic platelet-rich plasma for knee osteoarthritis combined with hematologic blood dyscrasias with platelet dysfunction: protocol of a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Zhu","year":"2022","journal-title":"BMC Musculoskelet Disord"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"25209","DOI":"10.1038\/s41598-024-75090-0","article-title":"Efficacy and safety of allogeneic platelet-rich plasma in chronic wound treatment: a meta-analysis of randomized controlled trials","volume":"14","author":"Li","year":"2024","journal-title":"Sci Rep"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1177\/0363546516637176","article-title":"Platelet-rich plasma activates proinflammatory signaling pathways and induces oxidative stress in tendon fibroblasts","volume":"44","author":"Hudgens","year":"2016","journal-title":"Am J Sports Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1625431","DOI":"10.3389\/fvets.2025.1625431","article-title":"Safety study of leucoreduced allogeneic pooled freeze-dried platelet-rich plasma in healthy equine joints","volume":"12","author":"Kooy","year":"2025","journal-title":"Front Vet Sci"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.2460\/javma.25.01.0033","article-title":"Intra-articular use of platelet-rich plasma and its derivatives in canine osteoarthritis: a systematic review","volume":"263","author":"Cardona-Ram\u00edrez","year":"2025","journal-title":"J Am Vet Med Assoc"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e51794","DOI":"10.7759\/cureus.51794","article-title":"Evaluation of the use of highly concentrated autologous platelet-rich plasma and platelet-rich fibrin membrane to improve the outcome in the management of severe dry eye disease, corneal neurotrophic ulcer and corneal burn","volume":"16","author":"Hassan","year":"2024","journal-title":"Cureus"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"102091","DOI":"10.1016\/j.clae.2023.102091","article-title":"Platelet-rich plasma for treating dry eye disease - a systematic review and meta-analysis","volume":"47","author":"Akowuah","year":"2024","journal-title":"Contact Lens Anterior Eye"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-026-07256-7","article-title":"Subconjunctival injectable platelet-rich fibrin for severe dry eye disease: preliminary clinical results","author":"Sabur","year":"2026","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2026.1870669\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T04:20:25Z","timestamp":1784521225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2026.1870669\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":47,"alternative-id":["10.3389\/fvets.2026.1870669"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2026.1870669","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"article-number":"1870669"}}